In this article, we will look at the 12 Best Healthcare Stocks Under $50 to Invest In.On January 27, Jared Holz, healthcare equity strategist at Mizuho, appeared on CNBC’s ‘Power Lunch’ to talk about healthcare stocks and the new proposals around Medicare Advantage. CNBC reported that the Trump administration proposed basically no change for most Medicare Advantage payments, as the plan called for a net average payment increase of a mere 0.09% next year, which appears to be an insignificant number and well ...

Company Overview - Genmab A/S (NASDAQ:GMAB) is a biotechnology company specializing in oncology, focusing on developing innovative antibody-based therapies for cancer treatment [3] Recent Developments - H.C. Wainwright has cut its price target for Genmab A/S from $41 to $39 while maintaining a Buy rating on the company's shares [1] - The price target adjustment follows the announcement that Genmab and partner AbbVie found no meaningful improvement in overall survival for EPKINLY (epcoritamab) monotherapy compared to standard treatments in second-line diffuse large B-cell lymphoma (DLBCL) patients [1] Future Outlook - Despite the recent trial results, H.C. Wainwright believes that EPKINLY will likely retain its 2023 accelerated clearance for third-line DLBCL treatment until the results of two additional ongoing Phase 3 trials are released [2] - The firm referenced Roche's Columvi as a precedent, which maintained its accelerated approval despite missing overall survival targets in a similar patient group while awaiting further study findings [2] Investment Considerations - While Genmab is recognized for its potential as an investment, there are opinions suggesting that certain AI stocks may offer greater upside potential and carry less downside risk [4]

Group 1 - Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) totaling USD 14,351 million in 2025, with USD 8,266 million from the U.S. and USD 6,085 million from the rest of the world [1][5] - Genmab receives royalties on the worldwide net sales of DARZALEX, which includes both intravenous and subcutaneous products, under an exclusive license agreement with Johnson & Johnson [1][5] - The company has a strong late-stage clinical pipeline and is focused on delivering transformative antibody-based medicines to patients [2] Group 2 - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, and has a global presence across North America, Europe, and Asia Pacific [3] - Genmab has been dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines for over 25 years [2]

Core Insights - Genmab A/S released topline results from the Phase 3 EPCORE DLBCL-1 trial of epcoritamab for diffuse large B-cell lymphoma (DLBCL), comparing it to standard chemotherapy options [1][2]. Study Details - The global study enrolled 483 patients with at least one prior line of therapy who were ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT) [2]. - The trial began in January 2021 and is still ongoing [2]. Data Findings - The study showed an overall survival (OS) hazard ratio of 0.96, which did not reach statistical significance [3]. - Epcoritamab monotherapy demonstrated improvements in progression-free survival (PFS), complete response rate, duration of response, and time to next treatment [3]. Safety Profile - Adverse events observed in the study were consistent with the known safety profile of epcoritamab [4]. - Ongoing analysis will consider various factors, including the impact of the COVID-19 pandemic and the availability of new anti-lymphoma therapies [4]. Future Steps - Full trial results will be presented at a future medical meeting, and Genmab will engage with global regulatory authorities for next steps [5]. - Data from two additional Phase 3 trials evaluating fixed-duration epcoritamab for DLBCL is anticipated in 2026 [5]. - Epcoritamab is already approved as Epkinly in the U.S. and Japan, and as Tepkinly in the European Union [5]. Analyst Commentary - Analysts expressed concerns about the EPCORE DLBCL-1 trial's failure to achieve significant OS results, raising questions about the current r/r DLBCL indication's accelerated approval status [6]. - Confidence remains in the upcoming EPCORE DLBCL-2 trial results in 2026, supported by strong Phase 2 results with Epkinly plus R-CHOP [6]. - Analysts believe it is unlikely that Epkinly will lose its accelerated approval status, citing precedents with other drugs [7]. Market Reaction - Genmab shares were down 2.36% at $31.49 at the time of publication [8].

Group 1 - Genmab A/S is recognized as one of the top oncology stocks to buy, with Deutsche Bank raising its price target for GMAB to DKK 2,400 from DKK 2,000 and maintaining a Buy rating, indicating strong analyst optimism regarding the company's late-stage oncology pipeline [1][3] - The company has partnered with AI research firm Anthropic to enhance its R&D capabilities through the use of agentic AI powered by Claude models, aiming for a more scalable and effective R&D process while maintaining human oversight [2] - Genmab specializes in developing innovative antibody-based therapies for cancer treatment, with its late-stage pipeline featuring promising programs such as Rina-S and Epkinly [3]

Industry Overview - The oncology market in the United States is projected to grow from an estimated $81.34 billion in 2025 to $211.78 billion by 2034, reflecting a compound annual growth rate (CAGR) of 11.75% driven by rising cancer rates and demand for personalized treatments [1] - Targeted treatments and monoclonal antibodies are leading sectors, with monoclonal antibodies expected to account for approximately 30% of market sales in 2024 [2] - Major trends include the integration of artificial intelligence (AI) in predicting patient responses to immunotherapy, with expected accuracy rates of 70%-80% by 2026 [3] Emerging Technologies - The oncology field is increasingly focusing on molecularly defined subsets of cancer, allowing for targeted therapies based on specific mutations rather than organ sites [4] - Therapeutic messenger RNA (mRNA) vaccines are in late-stage clinical trials, with potential approval anticipated between 2027 and 2029 [4] - Innovations such as Antibody-Drug Conjugates (ADCs), Bi-specific T-cell Engagers (TCEs), and non-invasive liquid biopsies are enhancing treatment efficacy and monitoring techniques [3][4] Company Highlights - Genmab A/S (NASDAQ:GMAB) is recognized for its innovative antibody-based therapies and has a promising late-stage oncology pipeline, including programs like Rina‑S and Epkinly [10][12] - Novartis AG (NYSE:NVS) has a robust oncology portfolio with over 30 high-value therapies and is investing in precision oncology and advanced manufacturing, including a new RLT facility in Florida as part of a $23 billion U.S. investment strategy [13][14][15]

Core Insights - Danish drugmaker Genmab's experimental drug for a type of blood cancer did not achieve its primary endpoint in a late-stage clinical trial [1] Company Summary - Genmab announced the failure of its experimental drug in a late-stage study, indicating a setback in its development pipeline [1]

Core Insights - Genmab announced topline results from the Phase 3 EPCORE DLBCL-1 trial, showing that epcoritamab monotherapy improved progression-free survival (PFS) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [1][2] - The trial demonstrated an overall survival (OS) hazard ratio of 0.96, which did not reach statistical significance [1] - Genmab and AbbVie will engage with global regulatory authorities to discuss next steps following the trial results [3] Study Details - The EPCORE DLBCL-1 trial enrolled 483 patients with R/R DLBCL, with 73% having received two or more prior lines of therapy [2] - The study compared epcoritamab monotherapy to investigator's choice of chemotherapy regimens, including rituximab plus gemcitabine and oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) [2][8] - The trial is ongoing and started on January 13, 2021 [8] Safety and Efficacy - Adverse events observed were consistent with the known safety profile of epcoritamab [3] - Further analysis of results is ongoing, considering factors like the COVID-19 pandemic and the availability of new anti-lymphoma therapies [3] Future Trials - Data is expected in 2026 from two additional Phase 3 trials evaluating epcoritamab in different treatment settings for DLBCL [4] - These trials include EPCORE DLBCL-2, assessing epcoritamab in combination with standard-of-care R-CHOP, and EPCORE DLBCL-4, comparing epcoritamab with lenalidomide against chemo-immunotherapy [4][12] Company Commitment - Genmab's CEO emphasized the significance of the EPCORE DLBCL-1 trial results in supporting epcoritamab as a core therapy for B-cell malignancies [5] - Epcoritamab has received regulatory approval in over 65 countries for certain lymphoma indications and is co-developed with AbbVie [5][11]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - Genmab is transitioning from a royalty-based company to a fully integrated, innovation-driven biotech firm with a focus on proprietary medicines and a robust late-stage pipeline, positioning itself for sustainable long-term growth into the 2030s [2][3]. Group 1: Company Overview - Genmab has evolved over the past decade, enhancing its portfolio and capabilities [2]. - The company is now characterized by a diversified revenue base and three high-impact late-stage programs [2]. Group 2: Growth Strategy - The company aims to leverage its high-quality revenue base and late-stage portfolio to drive sustainable growth well into the next decade [3].